Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

L Bodei, Dik Kwekkeboom, M Kidd, IM Modlin, EP Krenning

Research output: Contribution to journalArticleAcademicpeer-review

84 Citations (Scopus)

Abstract

Peptide receptor radionuclide therapy (PRRT) has been utilized for more than two decades and has been accepted as an effective therapeutic modality in the treatment of inoperable or metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs) or neuroendocrine tumors NETs). The two most commonly used radiopeptides for PRRT, Y-90-octreotide and Lu-177-octreotate, produce disease-control rates of 68%-94%, with progression-free survival rates that compare favorably with chemotherapy, somatostatin analogues, and newer targeted therapies. In addition, biochemical and symptomatic responses are commonly observed. In general, PRRT is well tolerated with only low to moderate toxicity in most individuals. In line with the need to place PRRT in the therapeutic sequence of gastroenteropancreatic NENs, a recently sponsored phase III randomized trial in small intestine NENs treated with Lu-177-octreotate vs high-dose octreotide long-acting release demonstrated that Lu-177-octreotate significantly improved progression-free survival. Other strategies that are presently being developed include combinations with targeted therapies or chemotherapy, intra-arterial PRRT, and salvage treatments. Sophisticated molecular tools need to be incorporated into the management strategy to more effectively define therapeutic efficacy and for an early identification of adverse events. The strategy of randomized controlled trials is a key issue to standardize the treatment and establish the position of PRRT in the therapeutic algorithm of NENs. (C) 2016 Elsevier Inc. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)225-238
Number of pages14
JournalSeminars in Nuclear Medicine
Volume46
Issue number3
DOIs
Publication statusPublished - 2016

Research programs

  • EMC MM-01-40-01
  • EMC NIHES-03-30-01

Cite this